Small molecule · Inhibitor of Tubulin (TUBB) · developed by Sanofi Aventis Us
ApprovedFDA, May 1996
What is Docetaxel?
Docetaxel is a microtubule inhibitor that binds free tubulin and promotes its assembly into stable microtubules while inhibiting their disassembly, arresting mitosis in cells.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
Beizray, Docivyx, Taxotere, RP-56976, XRP6976
Drug type
Small molecule
Targets
Tubulin (TUBB)
Mechanism
Inhibitor of Tubulin (TUBB)
Pathways
Microtubule assembly and stabilization, Mitotic inhibition
Squamous Cell Carcinoma of the Head and Neck (Beizray)
Breast Cancer (Docivyx)
Non-small Cell Lung Cancer (Docivyx)
Castration-Resistant Prostate Cancer (Docivyx)
From the indications section of the FDA label (version of Dec 17, 2025). Read the full label for the exact wording, limitations and safety information.
Conditions studied
Non-small Cell CarcinomaNon-Small Cell Lung Cancer MetastaticNon-Small Cell Lung Carcinoma
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.